journal article·2024-05-14

Combination of S1–N–Terminal and S1–C–Terminal Domain Antigens Targeting Double Receptor-Binding Domains Bolsters Protective Immunity of a Nanoparticle Vaccine against Porcine Epidemic Diarrhea Virus

Dan Yang, Mingjun Su, Donghua Guo, Feiyu Zhao, Meijiao Wang, Jiaying Liu, Jingxuan Zhou, Ying Sun, Xu Yang, Shanshan Qi, Zhen Li, Qinghe Zhu, Xiaoxu Xing, Chunqiu Li, Yang Cao, Li Feng, Dongbo Sun

ACS Nano· Volume 18· Issue 19
Publisher page

Abstract

Variants of coronavirus porcine epidemic diarrhea virus (PEDV) frequently emerge, causing an incomplete match between the vaccine and variant strains, which affects vaccine efficacy. Designing vaccines with rapidly replaceable antigens and high efficacy is a promising strategy for the prevention of infection with PEDV variant strains. In our study, three different types of self-assembled nanoparticles (nps) targeting receptor-binding N-terminal domain (NTD) and C-terminal domain (CTD) of S1 protein, named NTDnps, CTDnps, and NTD/CTDnps, were constructed and evaluated as vaccine candidates against PEDV. NTDnps and CTDnps vaccines mediated significantly higher neutralizing antibody (NAb) titers than NTD and CTD recombinant proteins in mice. The NTD/CTDnps in varying ratios elicited significantly higher NAb titers when compared with NTDnps and CTDnps alone. The NTD/CTDnps (3:1) elicited NAb with titers up to 92.92% of those induced by the commercial vaccine. Piglets immunized with NTD/CTDnps (3:1) achieved a passive immune protection rate of 83.33% of that induced by the commercial vaccine. NTD/CTDnps (3:1) enhanced the capacity of mononuclear macrophages and dendritic cells to take up and present antigens by activating major histocompatibility complex I and II molecules to stimulate humoral and cellular immunity. These data reveal that a combination of S1-NTD and S1-CTD antigens targeting double receptor-binding domains strengthens the protective immunity of nanoparticle vaccines against PEDV. Our findings will provide a promising vaccine candidate against PEDV.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Animal Virus Infections Studies · SARS-CoV-2 and COVID-19 Research · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing 163319, P. R. China

State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, P. R. China

Funding

National Natural Science Foundation of China · Key Research and Development??Program Guidance Projects of Heilongjiang Province of China · Key Project of Natural Science Foundation of Heilongjiang Province of China

References (94)

Show source-provided references
1. 10.1056/NEJMoa03074710.1056/NEJMoa030747 ↗
2. 10.1056/NEJMoa121172110.1056/NEJMoa1211721 ↗
3. 10.1038/s41586-018-0010-910.1038/s41586-018-0010-9 ↗
4. 10.1038/s41586-020-2008-310.1038/s41586-020-2008-3 ↗
5. 10.1038/s41586-021-04111-z10.1038/s41586-021-04111-z ↗
6. 10.1007/BF0131760610.1007/BF01317606 ↗
7. 10.3201/eid1808.12000210.3201/eid1808.120002 ↗
8. 10.1111/tbed.1299110.1111/tbed.12991 ↗
9. 10.1292/jvms.15-044610.1292/jvms.15-0446 ↗
10. 10.1111/tbed.1343910.1111/tbed.13439 ↗
11. 10.1111/tbed.1344410.1111/tbed.13444 ↗
12. 10.1016/j.virusres.2016.05.02310.1016/j.virusres.2016.05.023 ↗
13. 10.3201/eid2010.14049110.3201/eid2010.140491 ↗
14. 10.1016/j.meegid.2019.01.02210.1016/j.meegid.2019.01.022 ↗
15. 10.1099/jgv.0.00041910.1099/jgv.0.000419 ↗
16. 10.1186/s12917-016-0697-510.1186/s12917-016-0697-5 ↗
17. 10.1111/tbed.1294510.1111/tbed.12945 ↗
18. 10.1186/s13567-015-0278-910.1186/s13567-015-0278-9 ↗
19. 10.1016/j.vetmic.2019.02.01810.1016/j.vetmic.2019.02.018 ↗
20. 10.1186/s13567-017-0472-z10.1186/s13567-017-0472-z ↗
21. 10.1007/s00705-015-2694-610.1007/s00705-015-2694-6 ↗
22. 10.1128/JVI.77.16.8801-8811.200310.1128/JVI.77.16.8801-8811.2003 ↗
23. 10.1016/j.cell.2020.11.03210.1016/j.cell.2020.11.032 ↗
24. 10.1016/j.micpath.2020.10455310.1016/j.micpath.2020.104553 ↗
25. 10.1016/j.vetmic.2016.11.02910.1016/j.vetmic.2016.11.029 ↗
26. 10.1016/j.vaccine.2020.06.00910.1016/j.vaccine.2020.06.009 ↗
27. 10.1186/s12917-021-02885-y10.1186/s12917-021-02885-y ↗
28. 10.1007/s00705-020-04567-w10.1007/s00705-020-04567-w ↗
29. 10.1111/jam.1365210.1111/jam.13652 ↗
30. 10.1038/s41541-021-00283-x10.1038/s41541-021-00283-x ↗
31. 10.1016/j.virol.2021.10.01010.1016/j.virol.2021.10.010 ↗
32. 10.1099/jgv.0.00100110.1099/jgv.0.001001 ↗
33. 10.3390/pathogens1009111510.3390/pathogens10091115 ↗
34. 10.1128/jvi.00406-1910.1128/jvi.00406-19 ↗
35. 10.1016/j.vaccine.2017.10.05410.1016/j.vaccine.2017.10.054 ↗
36. 10.3390/vaccines912141610.3390/vaccines9121416 ↗
37. 10.3390/v1210112210.3390/v12101122 ↗
38. 10.3389/fphar.2021.65306410.3389/fphar.2021.653064 ↗
39. 10.1007/s00705-014-2163-710.1007/s00705-014-2163-7 ↗
40. 10.1155/2019/853027310.1155/2019/8530273 ↗
41. 10.1007/s11240-020-01835-010.1007/s11240-020-01835-0 ↗
42. 10.1038/nature1220210.1038/nature12202 ↗
43. 10.1038/s41467-020-20654-710.1038/s41467-020-20654-7 ↗
44. 10.1126/scitranslmed.abi573510.1126/scitranslmed.abi5735 ↗
45. 10.1038/s41541-021-00392-710.1038/s41541-021-00392-7 ↗
46. 10.1021/acscentsci.0c0140510.1021/acscentsci.0c01405 ↗
47. 10.1002/advs.20210537810.1002/advs.202105378 ↗
48. 10.1128/mbio.00230-2110.1128/mbio.00230-21 ↗
49. 10.1073/pnas.210643311810.1073/pnas.2106433118 ↗
50. 10.1038/s41423-021-00643-610.1038/s41423-021-00643-6 ↗
51. 10.1016/j.immuni.2020.11.01510.1016/j.immuni.2020.11.015 ↗
52. 10.1021/acsnano.0c0837910.1021/acsnano.0c08379 ↗
53. 10.1126/sciadv.abf159110.1126/sciadv.abf1591 ↗
54. 10.1093/femsre/fuaa05710.1093/femsre/fuaa057 ↗
55. 10.3390/v1402035110.3390/v14020351 ↗
56. 10.1016/j.cell.2020.10.04310.1016/j.cell.2020.10.043 ↗
57. 10.1016/j.chom.2021.04.01010.1016/j.chom.2021.04.010 ↗
58. 10.1016/j.cell.2021.03.02910.1016/j.cell.2021.03.029 ↗
59. 10.1126/science.abc695210.1126/science.abc6952 ↗
60. 10.1016/j.cell.2021.06.00510.1016/j.cell.2021.06.005 ↗
61. 10.1016/j.cell.2021.05.03210.1016/j.cell.2021.05.032 ↗
62. 10.1016/j.cell.2021.03.02810.1016/j.cell.2021.03.028 ↗
63. 10.1126/science.abg526810.1126/science.abg5268 ↗
64. 10.1016/j.chom.2021.03.00510.1016/j.chom.2021.03.005 ↗
65. 10.1038/s41590-021-01068-z10.1038/s41590-021-01068-z ↗
66. 10.1093/nsr/nwab05310.1093/nsr/nwab053 ↗
67. 10.1128/mBio.02473-2110.1128/mBio.02473-21 ↗
68. 10.1016/j.immuni.2021.03.02310.1016/j.immuni.2021.03.023 ↗
69. 10.1016/j.immuni.2022.04.00310.1016/j.immuni.2022.04.003 ↗
70. 10.1006/smim.1998.013610.1006/smim.1998.0136 ↗
71. 10.1038/nri330710.1038/nri3307 ↗
72. 10.1128/jvi.00647-2010.1128/jvi.00647-20 ↗
73. 10.1128/JVI.78.9.4638-4645.200410.1128/JVI.78.9.4638-4645.2004 ↗
74. 10.1016/S0168-1702(96)01390-110.1016/S0168-1702(96)01390-1 ↗
75. 10.1128/jvi.01279-2010.1128/jvi.01279-20 ↗
76. Bourne F. J. · Immunology · 1973 · 24 · 157
77. 10.1016/j.virusres.2016.05.01610.1016/j.virusres.2016.05.016 ↗
78. 10.1038/s41598-017-11160-w10.1038/s41598-017-11160-w ↗
79. Abbas A. K. · 2022
80. 10.2174/221173850766619102416204210.2174/2211738507666191024162042 ↗
81. 10.1080/14760584.2021.198489010.1080/14760584.2021.1984890 ↗
82. 10.1146/annurev-immunol-101819-02514610.1146/annurev-immunol-101819-025146 ↗
83. 10.3389/fimmu.2020.0127610.3389/fimmu.2020.01276 ↗
84. 10.3390/microorganisms710040210.3390/microorganisms7100402 ↗
85. 10.1084/jem.184.2.74710.1084/jem.184.2.747 ↗
86. 10.4049/jimmunol.161.9.458310.4049/jimmunol.161.9.4583 ↗
87. 10.1016/j.vaccine.2010.03.07910.1016/j.vaccine.2010.03.079 ↗
88. 10.4049/jimmunol.158.6.271310.4049/jimmunol.158.6.2713 ↗
89. 10.1016/j.micpath.2019.10392210.1016/j.micpath.2019.103922 ↗
90. 10.1016/j.vetmic.2019.10840010.1016/j.vetmic.2019.108400 ↗
91. 10.1093/nar/gku34010.1093/nar/gku340 ↗
92. 10.1126/science.abf684010.1126/science.abf6840 ↗
93. 10.1021/bm400930k10.1021/bm400930k ↗
94. 10.1371/journal.pone.016056110.1371/journal.pone.0160561 ↗